3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
CNS
1
Conditions
Melanoma
4
Carcinoma, Renal Cell
3
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Recurrence
2
Neoplasm Metastasis
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Stomach Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Neuroblastoma
1
Neoplasms
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Glioma
1
Ependymoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Merkel Cell
1
Interventions
pembrolizumab
44
Nivolumab
29
Gemcitabine
28
Paclitaxel
19
Cisplatin
18
Ipilimumab
15
Carboplatin
14
Cyclophosphamide
13
Capecitabine
12
Dexamethasone
10
Bevacizumab
10
cemiplimab
9
Irinotecan
9
Docetaxel
9
Albumin-Bound Paclitaxel
9
130-nm albumin-bound paclitaxel
9
spartalizumab
8
Pemetrexed
8
Sorafenib
7
Rituximab
7
Cetuximab
7
fludarabine
6
Temozolomide
6
Taxes
6
Radiotherapy
6
Leucovorin
6
Fluorouracil
6
Azacitidine
6
Ascorbic Acid
6
lenvatinib
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Neoplasms
×
bempegaldesleukin
×
Clear all
NCT04730349
2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2
Terminated
15 enrolled
14 charts